The FDA rejected Lykos Therapeutics’ application for MDMA-assisted therapy for PTSD, citing three specific concerns: gaps in safety reporting, insufficient evidence that benefits lasted over time, and questions about who was enrolled in the trials. The MDMA...
RFK Jr. psychedelic therapy support has brought real political attention to substances like psilocybin, MDMA, and ibogaine. For seekers already exploring this space, the shift matters. It does not, however, change what responsible engagement looks like at the...
Psychedelic therapy for veterans is one of the most actively researched areas in mental health today. Clinical trials involving MDMA and psilocybin have shown meaningful reductions in PTSD symptoms for people who found little relief through conventional care. This...
Texas has committed $50 million to fund clinical trials for ibogaine treatment Texas programs focused on veterans and first responders. The research is early and the risks are real, but the implications for PTSD, addiction, and traumatic brain injury are significant...
